British Patient Capital invests £90m London biotech company July 8, 2024 British Patient Capital recently also invested £10m into biotech firm Curve Therapeutics to support its cancer drug discovery technology.
UK less ready for next pandemic than before Covid – Oxford vaccinologist July 3, 2024 The UK's state apparatus is less prepared to deal with a pandemic today than it was before Covid, one of the professors in charge of the Oxford Astrazeneca vaccine rollout has warned.
GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines July 3, 2024 GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise them.
US drug giant Pfizer beats GSK to UK government contract for 4.9m vaccine shots June 25, 2024 Pfizer has beaten GSK to win a contract to supply millions of doses of a new respiratory vaccine in the UK after the government snubbed the local drugmaker.
Alliance Pharma sees profit and revenue spike amid ongoing uncertainty June 19, 2024 Alliance Pharma has hailed its strong second half performance for helping it to record sales and additional profit expansion in its preliminary results despite the healthcare group having delayed its audited results three times this year.
GSK: Good news for pharma giant as approval granted to expand vaccine use June 10, 2024 The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to affect younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.
Angle: Pharma firm’s share price plunges after missing market forecasts June 5, 2024 Angle also today announced a plan to raise about £8.5m through a combination of new share placements and subscriptions.
Astrazeneca swallows up Canada-based Fusion Pharmaceuticals in £1.5bn move June 5, 2024 Astrazeneca has completed its $2bn (£1.5bn) acquisition of Canada-based Fusion Pharmaceuticals, in a deal first announced in March.
GSK: How much could the Zantac lawsuits cost? June 3, 2024 Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.
Boots: Profit surges at British icon as owner mulls £7bn London float May 29, 2024 Historic pharmacy chain Boots has reported a surge in its pre-tax profit for its latest financial year amid reports its owner is considering a £7bn float in London.